147 related articles for article (PubMed ID: 19941080)
1. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
[TBL] [Abstract][Full Text] [Related]
2. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.
Nakashima S; Natsugoe S; Matsumoto M; Kijima F; Takebayashi Y; Okumura H; Shimada M; Nakano S; Kusano C; Baba M; Takao S; Aikou T
Anticancer Res; 2000; 20(3B):1933-7. PubMed ID: 10928129
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Matsumoto M; Yokomakura N; Uchikado Y; Takatori H; Ishigami S; Takao S; Aikou T
J Surg Oncol; 2005 Jul; 91(1):84-9. PubMed ID: 15999354
[TBL] [Abstract][Full Text] [Related]
6. [Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53].
Seitz JF; Perrier H; Monges G; Giovannini M; Gouvernet J
Gastroenterol Clin Biol; 1995 May; 19(5):465-74. PubMed ID: 7589997
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
Aroori S; Parshad R; Kapoor A; Gupta SD; Kumar A; Chattophadyay TK
Indian J Cancer; 2004; 41(1):3-7. PubMed ID: 15105572
[TBL] [Abstract][Full Text] [Related]
9. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
[TBL] [Abstract][Full Text] [Related]
10. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma.
Akita H; Doki Y; Miyata H; Hirao T; Yano M; Takachi K; Miyashiro I; Sasaki Y; Ishikawa O; Ohigashi H; Imaoka S
J Surg Oncol; 2006 Apr; 93(5):401-9. PubMed ID: 16550577
[TBL] [Abstract][Full Text] [Related]
12. [p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].
Cutilli T; Papola F; Di Emidio P; Leocata P; Corbacelli A
Minerva Stomatol; 1998; 47(1-2):1-9. PubMed ID: 9578641
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma.
Kunisaki C; Imada T; Yamada R; Hatori S; Kinbara K; Watai K; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Shimada H
Hepatogastroenterology; 2006; 53(69):366-71. PubMed ID: 16795974
[TBL] [Abstract][Full Text] [Related]
14. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma.
Ribeiro U; Finkelstein SD; Safatle-Ribeiro AV; Landreneau RJ; Clarke MR; Bakker A; Swalsky PA; Gooding WE; Posner MC
Cancer; 1998 Jul; 83(1):7-18. PubMed ID: 9655287
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
He LR; Liu MZ; Li BK; Rao HL; Deng HX; Guan XY; Zeng YX; Xie D
Cancer Sci; 2009 Sep; 100(9):1591-6. PubMed ID: 19552757
[TBL] [Abstract][Full Text] [Related]
16. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
17. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
18. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
Iizuka N; Hirose K; Noma T; Hazama S; Tangoku A; Hayashi H; Abe T; Yamamoto K; Oka M
Br J Cancer; 1999 Oct; 81(3):469-75. PubMed ID: 10507772
[TBL] [Abstract][Full Text] [Related]
19. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
20. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
